Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

ClinicalTrials.gov ID: NCT01844115

Public ClinicalTrials.gov record NCT01844115. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

Study identification

NCT ID
NCT01844115
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Forest Laboratories
Industry
Enrollment
415 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2013
Primary completion
Mar 30, 2014
Completion
Mar 30, 2014
Last update posted
Dec 17, 2019

2013 – 2014

United States locations

U.S. sites
36
U.S. states
16
U.S. cities
32
Facility City State ZIP Site status
Forest Investigative Site 023 Birmingham Alabama 35216
Forest Investigative Site 013 Phoenix Arizona 85032
Forest Investigative Site 036 Beverly Hills California 90210
Forest Investigative Site 001 Costa Mesa California 92626
Forest Investigative Site 009 Oceanside California 92056
Forest Investigative Site 026 Rancho Mirage California 92270
Forest Investigative Site 017 Sherman Oaks California 91403
Forest Investigative Site 034 Sherman Oaks California 91403
Forest Investigative Site 030 Bradenton Florida 34201
Forest Investigative Site 029 Gainesville Florida 32607
Forest Investigative Site 035 Jacksonville Florida 32256
Forest Investigative Site 032 Orlando Florida 32806
Forest Investigative Site 021 West Palm Beach Florida 33407
Forest Investigative Site 025 Atlanta Georgia 30328
Forest Investigative Site 018 Decatur Georgia 30030
Forest Investigative Site 022 Hoffman Estates Illinois 60169
Forest Investigative Site 014 Berlin New Jersey 08009
Forest Investigative Site 005 Cherry Hill New Jersey 08002
Forest Investigative Site 015 Albuquerque New Mexico 87109
Forest Investigative Site 028 Brooklyn New York 11214
Forest Investigative Site 010 Brooklyn New York 11235
Forest Investigative Site 002 Cedarhurst New York 11516
Forest Investigative Site 004 Mount Kisco New York 10549
Forest Investigative Site 003 New York New York 10003
Forest Investigative Site 007 New York New York 10021
Forest Investigative Site 020 New York New York 10168
Forest Investigative Site 027 The Bronx New York 10467
Forest Investigative Site 019 Dayton Ohio 45417
Forest Investigative Site 008 Portland Oregon 97210
Forest Investigative Site 037 Allentown Pennsylvania 18104
Forest Investigative Site 011 Media Pennsylvania 19063
Forest Investigative Site 033 Memphis Tennessee 38119
Forest Investigative Site 031 Dallas Texas 75231
Forest Investigative Site 012 Herndon Virginia 20170
Forest Investigative Site 016 Bellevue Washington 98007
Forest Investigative Site 024 Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01844115, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01844115 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →